Pérez de Isla, Leopoldo <br/><br/>
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.  [electronic resource] 

 -  Atherosclerosis  07 2019 
 - 40-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-1484 
<br/><br/><label>Standard No.: </label>10.1016/j.atherosclerosis.2019.05.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Cholesterol, LDL--blood<br/>Heterozygote<br/>Humans<br/>Hyperlipoproteinemia Type II--blood<br/>Immunologic Factors--therapeutic use<br/>Mathematical Concepts<br/>Proprotein Convertase 9--immunology<br/>Prospective Studies<br/>Risk Assessment